TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					111	cket No. 226.25.1
In Re A	pplication Of	f: William J. Ketcl	herside, Jr., et al.	27 7006		-
Applic	cation No.	Filing Date	Examiner	stomer No.	Group Art Unit	Confirmation No.
10/	773,106	02/05/2004	POPE, DARYL C	022913	2632	3980
		IETHOD, AND COM INFORMATION SY	APUTER PROGRAM FOR IN	TERFACING A	N EXPERT SYSI	ГЕМ ТО А
			Address to:  Commissioner for Pate P.O. Box 1450  Alexandria, VA 22313-			
			37 CFR 1.97(b)			
1.	of a nation three mont application	nal application other ths of the date of en i; before the mailing	atement submitted herewith is than a continued prosecution try of the national stage as sof a first Office Action on the est for continued examination	n application und et forth in 37 CF merits, or before	der 37 CFR 1.53 R 1.491 in an in the mailing of a	3(d); within iternational
2. 🗵	<ul> <li>37 CFR 1.97(c)</li> <li>The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</li> </ul>					
	☐ the s	statement specified i	n 37 CFR 1.97(e);			
			OR			
☐ the fee set forth in 37 CFR 1.17(p).						

TRANSMITT	AL OF INFORMA (Under 37 CF)	ATION DISCLOS R 1.97(b) or 1.97(	/0	TEMENT &		cket No. 26.25.1
In Re Application o	f: William J. Ketc	herside, Jr., et al.	S MN 8	7 2006		
Application No.	Filing Date	Examine	r War	tomer No.	Group Art Unit	Confirmation No.
10/773,106	02/05/2004	POPE, DARY	YL C	022913	2632	3980
-	METHOD, AND COM INFORMATION SY		M FOR INT	ERFACING AN	N EXPERT SYST	ГЕМ ТО А
	(Only cor	Paymonplete if Applicant elec	ent of Fee	fee set forth in 37	CFR 1.17(p))	
☐ The Director as describer ☐ Ch☐ Ch☐ ☐ Ch☐ ☐ Ch☐ ☐ Ch☐ ☐ Ch☐ ☐ Ch☐ ☐ WARNING	the amount of or is hereby authorized below. arge the amount of edit any overpayment arge any additional for credit card. Form Post in this form. Provident	t. ee required. TO-2038 is attached is form may becom	dit Deposit d. e public. O	redit card info	rmation should	I not be
I certify that this account is bein Patent and Trace	ate of Transmission b s document and authoriza ng facsimile transmitted demark Office (Fa	tion to charge deposit	I hereby of with the Uas first "Commiss	certify that this con Inited States Posta class mail in	respondence is bei al Service with suffic an envelope ac P.O. Box 1450, Ale on	ng deposited cient postage ddressed to
(Date)				(Date)		
	Signature			Signature of Per	son Mailing Correspo	ondence
Typed or	Printed Name of Person Sig	ning Certificate	Тур	ed or Printed Name	of Person Mailing Ce	ertificate
*This certific deposit according to the deposi	Signature eants	if paying by	Dated:	June 27, 2006		

cc:

PRESS MAIL LABEL NO.: EV 912 289 275 US

PATENT APPLICATION Docket No.: 15226.25.1

2/		
IN THE UNIT	TED STATES PATENT AND TRADEMARK OF	FICE
re application of:		)
	William J. Ketcherside, Jr., et al.	)
Serial No.:	10/773,106	) ) Art Unit
Filed:	February 5, 2004	) 2632
Confirmation No.:	3980	)
For:	SYSTEM, METHOD, AND COMPUTER PROGRAM FOR INTERFACING AN EXPERT SYSTEM TO A CLINICAL INFORMATION SYSTEM	) ( ) ( )
Examiner:	Daryl C. Pope	)
Customer No.:	022913	<i>)</i> )

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Please find, pursuant to 37 C.F.R. § 1.98(a)(1), the enclosed Form PTO-1449 which contains a list of all patents, publications, or other items that have come to the attention of one or more of the individuals designated in 37 C.F.R. § 1.56(c). While no representation is made that any of these references may be "prior art" within the meaning of that term under 35 U.S.C. §§

06/29/2006 CCHAU1

00000024 10773106

02 FC:1806

180.00 DP

102 or 103, the enclosed list of references is disclosed so as to fully comply with the duty of

disclosure set forth in 37 C.F.R. § 1.56.

Moreover, while no representation is made that a specific search of office files or patent

office records has been conducted or that no better art exists, the undersigned attorney of record

believes that the enclosed art is the closest to the claimed invention (taken in its entirety) of

which the undersigned is presently aware, and no art which is closer to the claimed invention

(taken in its entirety) has been knowingly withheld.

In accordance with 37 C.F.R. §§ 1.97 and 1.98, a copy of each of the listed references or

relevant portion thereof is also enclosed.

Dated this 27<sup>th</sup> day of June, 2006.

Respectfully submitted,

FRASER D. ROY

Attorney for Applicant Registration No. 45,666

Customer No. 022913

FDR:kc

KC0000005983V001

2

		OLP E 40			Sheet 1 of 6
	FORM PTO-1449	UN 2 7 2006	Atty. Docket No.: 15226.25.1	Serial No.: 10/773,106	
LIST OF PATENTS AND PUBLICANTIONS FOR APPLICANT'S INFORMATIONDISCLOSURE		Applicant: William J. Ketcherside, Jr. et al.			
	STATE	EMENT	Filing Date:	Group Art:	
			02/05/2004	2632	

## U.S. PATENTS

Exam Initi	Document No.	Date	Name	Class	Sub Class	Filing Date If Appropriate
	6,188,988	02/13/2001	Barry et al.	705	3	03/10/2000
	6,081,786	06/27/2000	Barry et al.	705	3	04/01/1999

## U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initial	Document No.	Date	Name	Class	Sub Class	Filing Date If Appropriate
	2004/0260666	12/23/2004	Pestotnik et al.	706	46	09/09/2003
	2002/0002472	01/03/2002	Abraham-Fuchs et al.	705	3	04/18/2001

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

"ADE Assistant." <u>www.theradoc.com</u> . November 13, 2005. <a href="http://www.theradoc.com/products/products_ade.html">http://www.theradoc.com/products/products_ade.html</a>
"Antibiotic Assistant – Antibiotic Assistant Overview." <a href="www.theradoc.com">www.theradoc.com</a> . November 13, 2005. <a href="http://www.theradoc.com/products/products_abxassist.html">http://www.theradoc.com/products/products_abxassist.html</a> >
"Antibiotic Assistant – Integrated Model." <u>www.theradoc.com</u> . November 13, 2005. <a href="http://www.theradoc.com/products/products_integrated.html">http://www.theradoc.com/products/products_integrated.html</a> >
Bates DW, et al., "The Costs of Adverse Drug Events in Hospitalized Patients. Adverse Drug Events Prevention Study Group," <u>JAMA</u> 277.4 (January 22, 1997): 1 <a href="http://jama.ama-assn.org/cgi/content/abstract/277/4/307">http://jama.ama-assn.org/cgi/content/abstract/277/4/307</a> >
Burke JP, "Hospitals Enter the War Against Antibiotic Resistance," [editorial review] <u>Current Opinion on Infectious Diseases</u> 8 (1995): 269-271
Burke JP, et al., "A Retrospective Analysis of Twice-daily Cefotaxime Compared to Convetional Therapy for the Treatment of Infections in a USA Hospital," <u>Diagn Microbial Infect Dis</u> 22 (1995):167-69
Burke JP, et al., "Antibiotic Cycling: What Goes Around Comes Around," [editorial review] Current Opinion in Infectious Diseases 13 (2000): 367-69

EXAMINER: DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		Atty. Docket No.: 15226.25.1	Serial No.: 10/773,106	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATIONDISCLOSURE STATEMENT		Applicant: William J. Ketcherside, Jr. et al.		
		Filing Date: 02/05/2004	Group Art: 2632	
	Burke JP, et al., "Antibiotic Resistance Infectious Diseases 11 (1998): 441-43	ee: The Combat Zone," [editor	rial review] Current Opinion in	
	Burke JP, et al., "Antibiotic Resist [editorial review] Current Opinion in I	ance-Systems Thinking, Change of the change	nos and Complexity Theory," 317-19	
	Burke JP, et al., "Breaking the Chain in Infectious Diseases 9 (1996): 253-5.		itorial review] <u>Current Opinion</u>	
	Burke JP, et al., "Evaluation of the Hospitalized Patients," Rpt. from Clin	Financial Impact of Ketoroical Therapeutics 18.1 (1996):	lac Tromethamine Therapy in 197-211	
	Burke JP, et al., "Evaluation of the Impact of Implementation of a Comprehensive Computerized Antibiotic Management Program at Intermountain Health Care," Healthcare Information and Management Systems Society Proceedings 1 (1997): 18-24			
	Burke JP, et al., "Evaluation of Therapeutic Antibiotic Substitution by Microcosting Using an Automated Hospital Database," Abstracts of the 1991 ICAAC, The 31 <sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL (September 29 – October 2, 1991), Article 407: 167			
	Burke JP, et al., "Inappropriate An Clinical Research 36.1 (January 1988)		Using Computer Algorithms,"	
	Burke JP, et al., "The HELP System a Infection 18(Supp. A) (1991): 424-31	and Its Application to Infection	n Control," Journal of Hospital	
	Burke JP, et al., "The Pharmacy and DClinicians. Baltimore: Williams & Wil	Orug Usage," <u>Assessing Qualit</u> Ikins (1991): 509-20	y Health Care: Perspectives for	
	Burke JP, et al., "The Quality of Antibiotic Use and the Quality of Measuring It," [editorial review] Current Opinion in Infectious Diseases 10 (1997: 289-291			
	Burke JP, et al., Reply to Letters. JAM	<u>1A</u> 277.17 (May 7, 1997): 135	1-1353	
	Classen DC, et al., "Adverse Drug Events in Hospitalized Patients: Excess Length of Stay, Extra Costs, and Attributable Mortality," JAMA 277.4 (January 1997): 301-6			
	Classen DC, et al., "Adverse Effects of Intravenous Erythromycin in Hospital Patients: Attributable Costs and Excess Length of Stay," Abstracts of the 36 <sup>th</sup> ICAAC, American Society for Microbiology, New Orleans, Louisiana, Session 112 (September 15-18, 1996): Article N19: 296			
	Classen DC, et al., "Antibiotic Prophy England Journal of Medicine 327.3 (Ju		Pections," [To the Editor:] New	
	Classen DC, et al., "Case 12.1: I Transforming Health Care Through In Verlag New York NY (1995): 322-33	nformation Case Studies. NN		

FORM PTO-1449		Atty. Docket No.: 15226.25.1	Serial No.: 10/773,106	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATIONDISCLOSURE STATEMENT		Applicant: William J. Ketcherside, Jr. et al.		
		Filing Date: 02/05/2004	Group Art: 2632	
	Classen DC, et al., "Clinical and F Hospitalized Patients," Annals of Phar	Financial Impact of Intraveno macotherapy 33 (June 1999):	ous Erythromycin Therapy in 669-73	
	Classen DC, et al., "Clinical Evaluation Teaching Hospital," Abstracts of the Antimicrobial Agents and Chemothera	he $1992$ ICAAC, The $32^{nc}$	Interscience Conference on	
	Classen DC, et al., "Computerized Su JAMA 266.20 (November 27, 1991): 2		vents in Hospitalized Patients,"	
	Classen DC, et al., "Description of a Computerized Adverse Drug Event Monitor Using a Hos Information System," Hospital Pharmacy 27 (September 1992):774, 776-779, 783			
	Classen DC, et al., "Intensive Surveillance of Midazolam Use in Hospital Patients and the Occurrence of Cardiorespiratory Arrest," 12.3 Pharmacotherapy (1992): 213-16			
	Classen DC, et al., "Prophylactic Antibiotics Used to Prevent Surgical Wound Infections," <u>Clinica Practice Improvement: A New Technology for Developing Cost-Effective Quality Health Care New York: Faulkner &amp; Gray (1994): 217-21</u>			
	Classen DC, et al., "Surveillance for Information System," 12.4 Infection C			
	Classen DC, et al., "The Computer-Based Patient Record: An Essential Technology for Hospital Epidemiology," <u>Hospital Epidemiology and Infection Control</u> Ed. CG Mayhall, Williams. Baltimore, MD (1996): 123-137			
	Classen DC, et al., "The Impact of Managed Care and Capitation on the Practice of Infectious Disease: Strategies for Managing Clinical Care," Abstracts – 35 <sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy an Annual Meeting of the American Society for Microbiology San Francisco, CA (September 17-20, 1995): Article S19: 352			
		Classen DC, et al., "The Timing of Prophylactic Administration of Antibiotics and the Risk of Surgical-wound Infections," New England Journal of Medicine 326.5 (January 30, 1992): 281-86		
	Classen, DC, et al., "The Computer-Based Patient Record: An Essential Technology for Hospital Epidemiology," Hospital Epidemiology and Infection Control 2E. Ed. C. Glen Mayhall. Lippiacott Williams & Williams, Philadelphia, PA (1999): 141-154			
	Evans RS, et al., "A Computerized A Symp Comput Appl Med Care 11 (198		lactic Antibiotics," Proc Annu	
	Evans RS, et al., "A Decision Suppo Appl Med Care 19 (1995): 651-55	ort Tool for Antibiotic Therap	y," Proc Annu Symp Comput	
	Evans RS, et al., "Applications of I Susceptibility Testing 349 (1994): 87-9	Medical Informatics in Antib 96	niotic Therapy," Antimicrobial	

FORM PTO-1449		Atty. Docket No.: 15226.25.1	Serial No.: 10/773,106	
		Applicant:		
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATIONDISCLOSURE		William J. Ketcherside, Jr. e	t al.	
	STATEMENT	Filing Date:	Group Art:	
		02/05/2004	2632	
	ns RS, et al., "Computer Surveill <u>IA</u> 256.8 (August 22/29, 1986): 10		nfections and Antibiotic Use,"	
	ns RS, et al., "Computerized Idections," <u>American Journal of Infec</u>			
	ns RS, et al., "Development of a p Comput Appl Med Care 15 (199		g Event Monitor," Proc Annu	
	ns RS, et al., "Development of ar 3): 17-22	n Automated Antibiotic Cons	ultant," M.D. Computing 10.1	
Evar Cost	Evans RS, et al., "Evaluating the Impact of Computer-based Drug Monitoring on the Quality and Cost of Drug Therapy," <u>Hospital Information Systems</u> (1995): 201-220			
Cost Impa	Evans RS, et al., "Evaluating the Impact of Computer-based Drug Monitoring on the Quality an Cost of Drug Therapy," <u>Hospital Information Systems: Design and Development Characteristic Impact and Future Architecture</u> . Medical Artificial Intelligence Series. Amsterdam: Elsevier. (1998): 1-20			
Prog Cher	Evans RS, et al., "Experience with a Computer-Assisted Antiinfective Agent Manageme Program," <u>Computer-Assisted Decision-Making Activated by Clinical Laboratory Findings.</u> <u>Clem Lab Med Symposium Abstracts – IFCC-WorldLab '99. Firenze. 37 – Special Suppleme (June 6-11, 1999): S6</u>			
Evar <u>Arch</u>	ns RS, et al., "Improving Empirion Intern Med 154 (April 25, 1994):	c Antibiotic Selection Using 878-84	Computer Decision Support,"	
	ns RS, et al., "Prediction of Homated Hospital Database," <u>Proc A</u>			
	ns RS, et al., "Preventing Adv macotherapy 28 (April 1994): 523		italized Patients," Annals of	
	Evans RS, et al., "Prevention of Adverse Drug Events Through Computerized Surveillance," Proc Annu Symp Copmut Appl Med Care 16 (1992): 437-41			
	ns RS, et al., "Reducing the Durations of the Durations," <u>DICP, The Annu</u>			
Infor	ns RS, et al., "The Evaluation of rmation Services, Departments of Hospital and University of Utah S	f Medical Informatics, Infect	ious Diseases, and Pharmacy,	
	ns RS, et al., "Using a Hospital Ints," Proc Annu Symp Comput Ap	Information System to Assess the Effects of Adverse Drug opl Med Care 17 (1993): 161-65		

FORM PTO-1449		Atty. Docket No.: 15226.25.1	Serial No.: 10/773,106	
LIST OF PATENTS AND PUBLICATIONS FOR		Applicant: William J. Ketcherside, Jr. et al.		
APPLICANT'S INFORMATIONDISCLOSURE STATEMENT		William J. Retenerside, Jr. C		
		Filing Date:	Group Art:	
		02/05/2004	2632	
	Gundlapalli AV, et al., "A Rule-based Deployment by a Hospital Infection C as early as 2001	d Computer System to Facilita Control Unit," upon information	ate Public Health Surveillance: on and belief, available at least	
	Gundlapalli AV, et al., "Hospital El System Deployed During the 2002 W Conference, San Antonio, TX, Session	'inter Olympic Games," Prese	ed Public Health Surveillance ented in part at the 2003 APIC	
	Harbarth S, et al., "Clinical and Econo Nephrotoxicity," <u>CID</u> 35 (December 1		nal Amphotericin B-Associated	
	Harbarth S, et al., "The Epidemiology of Nephrotoxicity Associated with Conventional Amphotericin B Therapy," American Journal of Medicine 111 (November 2001): 528-534			
		Hongsermeier TM, et al., "TheraDoc Expert Systems: The Cornerstone of a Successful Infection Management and Patient Safety Strategy," White Paper, Salt Lake City: TheraDoc, Inc. (2003): 1-10		
		Kelly DL, et al., "Reengineering a Surgical Service Line: Focusing on Core Process Improvement," American Journal of Medical Quality 12.2 (1997): 120-29		
	Larsen RA, et al., "Improved Periopera Through Use of Computer Decision A 320			
	Leader WG, et al., "Integrating Pharmacokinet. 31.3 (September 1996)		re Information Systems," Clin.	
	[Abstract]," American Society for Mic	Lo TS., et al., "Secular Trends of Enterococcal Urinary Tract Infection: A Ten-Year Study [Abstract]," American Society for Microbiology, 1 <sup>st</sup> International ASM Conference on Enterococci, available at least as early as December 6, 1999: 1		
		Naranjo CA, et al., "A Method for Estimating the Probability of Adverse Drug Reaction," Clinical Pharmacology and Therapeutics 30.2 (August 1981): 239-245		
		Pestotnick SL, et al., "Medical Informatics: Meeting the Information Challenges of a Changing Health Care System," Journal of Informed Pharmacotherapy 2 (2000): 1		
	Pestotnik S, "The Future of ID Pha [editorial] Society of Infectious Diseas			
	Pestotnik SL, (August 1993). "Compunpublished masters thesis, University			
	Pestotnik SL, "Role of Information S Quality of the Medication Use Process York: Pharmaceutical Products Press/F	s: Error Prevention & Reducin	ng Adverse Drug Events. New	

**EXAMINER:** 

DATE CONSIDERED:

FORM PTO-1449	Atty. Docket No.: 15226.25.1	Serial No.: 10/773,106	
LIST OF PATENTS AND PUBLICATIONS FOR	Applicant:		
APPLICANT'S INFORMATIONDISCLOSURE	William J. Ketcherside, Jr. et	ı aı.	
STATEMENT	Filing Date:	Group Art:	
	02/05/2004	2632	
Pestotnik SL, et al., "A Five-Year A Hospital," Abstracts of the 33 <sup>rd</sup> ICAAC	Analysis of Parental Anti-info C. New Orleans, LA (October	ective Use at a Tertiary Care 17-20, 1993), 634: 235	
Pestotnik SL, et al., "Adverse Effect Attributable Costs and Excess Length of 35 <sup>th</sup> Annual Meeting 25.2 (August 1990)	of Stay," Clinical Infectious D	n (IVV) in Hospital Patients: Diseases, Abstracts of the IDSA	
Pestotnik SL, et al., "Expert Clinic Stewardship Programs," Pharmacothers	eal Decision Support System apy 25.8 (2005): 1116-25	ns to Enhance Antimicrobial	
Pestotnik SL, et al., "Expert Clinic Stewardship Programs," Society of Infe	Pestotnik SL, et al., "Expert Clinical Decision Support Systems to Enhance Antim Stewardship Programs," <u>Society of Infectious Diseases Pharmacists Newsletter</u> 14.3 (Winter 2-7		
Pestotnik SL, et al., "Medical Inform Perspective," <u>International Pharmace</u> 3505425: 817	Pestotnik SL, et al., "Medical Informatics, Decision Support, and Quality of Care: Clinician' Perspective," <u>International Pharmaceutical Abstracts</u> , Information Processing and Literature 3505425: 817		
Pestotnik SL, et al., "Prospective Surve Using a Hospital Information System,"			
Pestotnik SL, et al., "Surveillance Hospitalized Patients," Abstracts of Antimicrobial Agents and Chemothera	the 1992 ICAAC, The 32 <sup>nd</sup>	d Interscience Conference on	
Pestotnik SL, et al., "Therapeutic A Expert System," American Journal of 1	ntibiotic Monitoring: Surveil Medicine 88 (January 1990): 4	llance Using a Computerized 43-48	
Riley DK, et al., "The Effect of Improved Prophylactic and Therapeutic Anti Microbial Resistance Patterns," <u>Infection Control and Hospital Epidemiology</u>		tic Antibiotic Use on Hospital miology, S2 (April 1994): P26	
(CDSS) Utilized by the Rural Antibiot	Tettelbach W, et al., "Usage Evaluation of a Computerized Clinical Decision Support System (CDSS) Utilized by the Rural Antibiotic Decision-Support & Resistance (RADAR) Project," upon information and belief, available at least as early as 2001		
	Pestotnik SL, "E-Prescribing in the Hospital with the Theradoc System," 44 <sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC (October 30-November 2, 2004), (abst. 636)		
Classen DC, et al., "Antibiotic Outcon Use in Hospitalized Patients," Clin. Res	nes Research: A Large Rando s. 39.2 (1991): 373A	omized Trial of Cephalosporin	
Tettlebach WH, et al., "Usage Evaluation System," 42 <sup>nd</sup> ICAAC Abstracts, 42 <sup>nd</sup> Chemotherapy. San Diego, CA (Septer	<sup>na</sup> Interscience Conference c	on Antimicrobial Agents and	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.